| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-10-12 | CMB305 and atezolizumab | soft tissue sarcoma, locally advanced, relapsed, or metastatic NY-ESO-1+ synovial sarcoma or myxoid/round-cell liposarcoma. | 2 | Immune Design (USA - MA) | Cancer - Oncology |
| 2018-10-12 | CMB305 (LV305 and G305) - dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene05 | synovial sarcoma | 3 | Immune Design (USA - MA) | Cancer - Oncology |
| 2018-10-11 | lifileucel - LN-144 | metastatic melanoma | 2 | Lion Biotechnologies (USA - CA), now Iovance Biotherapeutics (USA - CA) | Cancer - Oncology |
| 2018-10-06 | LOXO-292 | RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors with increased RET activity | 1-2 | Loxo Oncology (USA - CT) | Cancer - Oncology |
| 2018-10-06 | Translarna™ (ataluren) | Duchenne muscular dystrophy | observational | PTC Therapeutics (USA - NJ) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-10-06 | Spinraza® (nusinersen) | spinal muscular atrophy (SMA) | 2 | Biogen (USA - MA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-10-05 | AT132 | X-Linked Myotubular Myopathy (XLMTM) | 1-2 | Audentes Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-10-05 | Orbactiv™ (oritavancin) | infections due to presumed or confirmed gram-positive bacteria | observational | Melinta Therapeutics (USA - CT) | Infectious diseases |
| 2018-10-04 | birinapant and pembrozilumab | treatment-resistant solid tumours | 1-2 | Medivir (Sweden) | Cancer - Oncology |
| 2018-10-03 | risdiplam - RG7916/RO7034067 | type 1spinal muscular atrophy (SMA) | 2 | PTC Therapeutics (USA - NJ) Roche (Switzerland) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-10-03 | AAVrh74.MHCK7.micro-Dystrophin | Duchenne muscular dystrophy (DMD) | 1-2 | Sarepta Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2018-10-03 | Biktarvy® (BIC/FTC/TAF - bictegravir (50 mg) and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) | HIV-1 infection in adults | 3 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2018-10-03 | ALN-AAT02 | AAT deficiency-associated liver disease (alpha-1 liver disease) | 1-2 | Alnylam Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Hepatic diseases - Liver diseases |
| 2018-10-02 | Kineret® (anakinra) | acute gout | 2 | Swedish Orphan Biovitrum - SOBI (Sweden) | Inflammatory diseases |
| 2018-10-01 | MIV-818 | advanced liver cancer including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma and liver metastases from solid tumors | 1-2 | Medivir (Sweden) | Cancer - Oncology |
| 2018-09-29 | IPH4102 | cutaneous T-cell lymphoma (CTCL) and especially their aggressive forms: Sezary Syndrome and Transformed Mycosis Fungoides | 1 | Innate Pharma (France) | Cancer - Oncology - Rare diseases |
| 2018-09-28 | ATOR-1017 | preclinical | Alligator Bioscience (Sweden) | Cancer - Oncology | |
| 2018-09-27 | givosiran (ALN-AS1) | acute hepatic porphyria | 3 | Alnylam Therapeutics (USA - MA) | Rare diseases - Metabolic diseases |
| 2018-09-26 | CSTD002-NK (adoptive NK cell therapy) | reduction of relapse in high risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) | 2 | Cytosen Therapeutics (USA - TX) | Cancer - Oncology |
| 2018-09-25 | Imfinzi® (durvalumab) (MEDI4736) | non-small cell lung cancer (NSCLC) | 3 | AstraZeneca (UK) | Cancer - Oncology |
